Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

NCT06780839 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage I, II, IIIA, IIIB

Interventions

DRUG: Ensartinib

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]